TY - JOUR
T1 - Interactions of 2,3,7,8-TCDD and PCB mixtures/congeners
T2 - Immunotoxicity studies
AU - Davis, D.
AU - Safe, S.
N1 - Funding Information:
The financial assistance of the National Institutes of Health (ES03843) and the Texas
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1990
Y1 - 1990
N2 - Several commercial PCBs, including Aroclors 1260, 1254, 1248, 1242 and 1232, were immunotoxic in C57BL/6 mice, however the results showed that the lower chlorinated biphenyls (Aroclor 1232 and 1242) were less toxic than the higher chlorinated mixtures. Treatment of C57BL/6J mice with an immunotoxic dose of 2,3,7,8-TCDD (3.7 nmol/kg) and a dose (25 mg/kg) of the commercial PCBs which was not immunotoxic showed that the PCB mixtures antagonized the 2,3,7,8-TCDD-mediated decrease in the plaque-forming cell response to sheep erythrocytes. The structure-dependent effects of individual PCB congeners to act as 2,3,7,8-TCDD antagonists were also investigated and only 2 compounds, namely 2,2′,4,4′,5,5′-and 2,3,3′,4,5,5′-hexachlorobiphenyl exhibited antagonist activity comparable to that observed for Aroclor 1254 as a 2,3,7,8-TCDD antagonist. The implications of these results will be discussed.
AB - Several commercial PCBs, including Aroclors 1260, 1254, 1248, 1242 and 1232, were immunotoxic in C57BL/6 mice, however the results showed that the lower chlorinated biphenyls (Aroclor 1232 and 1242) were less toxic than the higher chlorinated mixtures. Treatment of C57BL/6J mice with an immunotoxic dose of 2,3,7,8-TCDD (3.7 nmol/kg) and a dose (25 mg/kg) of the commercial PCBs which was not immunotoxic showed that the PCB mixtures antagonized the 2,3,7,8-TCDD-mediated decrease in the plaque-forming cell response to sheep erythrocytes. The structure-dependent effects of individual PCB congeners to act as 2,3,7,8-TCDD antagonists were also investigated and only 2 compounds, namely 2,2′,4,4′,5,5′-and 2,3,3′,4,5,5′-hexachlorobiphenyl exhibited antagonist activity comparable to that observed for Aroclor 1254 as a 2,3,7,8-TCDD antagonist. The implications of these results will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=0025071074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025071074&partnerID=8YFLogxK
U2 - 10.1016/0045-6535(90)90234-K
DO - 10.1016/0045-6535(90)90234-K
M3 - Article
AN - SCOPUS:0025071074
VL - 20
SP - 1141
EP - 1146
JO - Chemosphere
JF - Chemosphere
SN - 0045-6535
IS - 7-9
ER -